Rubicon Research operates out of five locations—the corporate HQ and R&D center in Thane, India, the R&D center in Concord, Canada, the manufacturing sites in Ambernath and Satara, India, and the business development and regulatory office in Plainsboro, US.
Established in 1999, the company operates out of its corporate headquarters in Thane. The 38,000 square feet office also houses the India R&D center. The R&D center has three formulation facilities. To know more visit our R&D page.
The 15,000 square feet facility offers comprehensive drug product formulation and process development, along with analytical testing services to the pharmaceutical industry. The center specializes in nasal and pulmonary drug delivery systems and otic, ophthalmic, and dermal products. To know more visit our R&D page.
Our 140,000+ square feet state-of-the-art manufacturing plant is focused on producing pharmaceutical products (Rx as well as over the counter), and supports scale up and commercialization in a range of oral solids. To know more visit our Manufacturing page.
The 50,000+ square feet manufacturing plant is focussed on producing oral-liquid pharmaceutical products. It can produce non-sterile oral solutions and suspensions and supports packaging in a variety of formats. To know more visit our Manufacturing page.
Rubicon Research’s partners are predominantly US and Canada-based and products are routinely submitted to the USFDA. Therefore, for ease of doing business, Rubicon Research has a Business Development and Regulatory Office in New Jersey.
If you’re in the US or Canada, connect with us at our New Jersey office to discuss new opportunities and ongoing projects. To set up an appointment, email us email@example.com.